Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Amer H. Zureikat"'
Autor:
Amer H. Zureikat, Ibrahim Nassour, David L Bartlett, Annissa Desilva, Lance A. Liotta, Aatur D. Singhi, Virginia Espina, Alessandro Paniccia, Samer AlMasri, Nathan Bahary, Brian A. Boone, Herbert J. Zeh, Patricia Loughran, Michael T. Lotze, Mazen S. Zenati
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 20, Pp 7233-7241 (2021)
Cancer Medicine, Vol 10, Iss 20, Pp 7233-7241 (2021)
Introduction Preoperative autophagy inhibition with hydroxychloroquine (HCQ) in combination with gemcitabine in pancreatic adenocarcinoma (PDAC) has been shown to be safe and effective in inducing a serum biomarker response and increase resection rat
Autor:
Nathan Bahary, Naomi Fei, Rajesh Ramanathan, Melissa E. Hogg, Sijin Wen, Brian A. Boone, Herbert J. Zeh, Amer H. Zureikat, Aatur D. Singhi, Michael T. Lotze
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 5, Pp 1822-1829 (2021)
Clinical and Translational Science
Clinical and Translational Science
SMAD4, a tumor suppressor gene, is lost in up to 60%–90% of pancreatic adenocarcinomas (PDAs). Loss of SMAD4 allows tumor progression by upregulating autophagy, a cell survival mechanism that counteracts apoptosis and allows intracellular recycling
Autor:
Alessandro Paniccia, Nathan Bahary, David L Bartlett, Kenneth K. Lee, Kenneth J. Smith, Amer H. Zureikat, Caroline J. Rieser, Sowmya Narayanan
Publikováno v:
J Surg Oncol
INTRODUCTION: Neoadjuvant therapy (NAT) is an emerging strategy for operable pancreatic ductal adenocarcinoma (PDAC). While neoadjuvant therapy increases multimodal therapy completion, it risks functional decline and treatment drop out. We used decis
Autor:
Alessandro Paniccia, Derek Barclay, Yoram Vodovotz, Jacob C. Hodges, Michael T. Lotze, Pranav Murthy, Amer H. Zureikat, Brian A. Boone, Randall E. Brand, Ruben Zamora, Kenneth K. Lee, Asmita Chopra, Richard L. Simmons
Publikováno v:
J Immunother
Despite its increased application in pancreatic ductal adenocarcinoma (PDAC), complete response to neoadjuvant therapy (NAT) is rare. Given the critical role of host immunity in regulating cancer, we sought to correlate baseline inflammatory profiles
Autor:
Andrew Lee, James F. Pingpank, Matthew P. Holtzman, Shannon Altpeter, Melanie Ongchin, Caroline J. Rieser, David L Bartlett, M. Haroon A. Choudry, Amer H. Zureikat, Lauren B Hall, Eliza Kang, Heather Jones
Publikováno v:
Ann Surg Oncol
INTRODUCTION: Early recurrence (ER) is a significant challenge for patients with colorectal peritoneal metastases (CRPM) following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS HIPEC). Preoperative risk stratification for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c35eb5532ddc82a4bef8b9c86688e0e8
https://europepmc.org/articles/PMC8666126/
https://europepmc.org/articles/PMC8666126/
Autor:
Quisette P. Janssen, Jacob L. van Dam, Laura R. Prakash, Deesje Doppenberg, Christopher H. Crane, Casper H.J. van Eijck, Susannah G. Ellsworth, William R. Jarnagin, Eileen M. O’Reilly, Alessandro Paniccia, Marsha Reyngold, Marc G. Besselink, Matthew H.G. Katz, Ching-Wei D. Tzeng, Amer H. Zureikat, Bas Groot Koerkamp, Alice C. Wei
Publikováno v:
Journal of the National Comprehensive Cancer Network, 20(7), 783-791. Cold Spring Publishing LLC
Journal of the National Comprehensive Cancer Network : JNCCN, 20(7), 783-791. Cold Spring Publishing LLC
J Natl Compr Canc Netw
Journal of the National Comprehensive Cancer Network : JNCCN, 20(7), 783-791. Cold Spring Publishing LLC
J Natl Compr Canc Netw
Background: The value of neoadjuvant radiotherapy (RT) after 5-fluorouracil with leucovorin, oxaliplatin, and irinotecan, with or without dose modifications [(m)FOLFIRINOX], for patients with borderline resectable (BR) pancreatic ductal adenocarcinom
Autor:
Samer AlMasri, Mazen Zenati, Abdulrahman Hammad, Ibrahim Nassour, Hao Liu, Melissa E. Hogg, Herbert J. Zeh, Brian Boone, Nathan Bahary, Aatur D. Singhi, Kenneth K. Lee, Alessandro Paniccia, Amer H. Zureikat
Publikováno v:
JAMA Network Open. 5:e2218355
Neoadjuvant therapy is increasingly used in localized pancreatic carcinoma, and survival is correlated with carbohydrate antigen 19-9 (CA19-9) levels and histopathologic response following neoadjuvant therapy. With several regimens now available, the
Autor:
Amr Al-abbas, Melissa E. Hogg, Caroline J. Rieser, Matthew D. Neal, Amer H. Zureikat, Mazen S. Zenati, Brian A. Boone, Ahmad Hamad, Herbert J. Zeh
Publikováno v:
Annals of Surgical Oncology. 26:1503-1511
Pancreatic ductal adenocarcinoma (PDA) is associated with a hypercoagulable state, resulting in a high risk of venous thromboembolism (VTE). Risk of VTE is well established for patients receiving chemotherapy for advanced disease and during the perio
Autor:
Jennifer L. Miller-Ocuin, Michael T. Lotze, Melissa E. Hogg, Allan Tsung, Amer H. Zureikat, Pranav Murthy, Natalie Seiser, David L. Bartlett, Nathan Bahary, Lance A. Liotta, Brian A. Boone, Kenneth K. Lee, Herbert J. Zeh, Daolin Tang, Daniel P. Normolle, Aatur D. Singhi, Virginia Espina, J. Wallis Marsh, Ravi K. Amaravadi
Publikováno v:
Clin Cancer Res
Purpose: We hypothesized that autophagy inhibition would increase response to chemotherapy in the preoperative setting for patients with pancreatic adenocarcinoma. We performed a randomized controlled trial to assess the autophagy inhibitor hydroxych
Autor:
Yongli Shuai, David L. Bartlett, Matthew P. Holtzman, Steven S. Ahrendt, Herbert J. Zeh, James F. Pingpank, Haroon A. Choudry, Heather L. Jones, Lekshmi Ramalingam, Amer H. Zureikat, Sam Pakraftar
Publikováno v:
Annals of Surgical Oncology. 24:3811-3817
Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion (CRS-HIPEC) is a complex procedure that often requires ostomy creation to protect high-risk anastomoses. This study aimed to evaluate the authors’ institutional experience with C